Nanotechnology in Early Breast Cancer Detection and Treatment
DOI:
https://doi.org/10.47611/jsrhs.v13i4.8303Keywords:
nanotechnology, breast cancer, detection, treatment, nanosensor, bifunctional nanoprobe, pH, preclinical, clinicalAbstract
Breast cancer is one of the leading causes of cancer deaths worldwide. Diagnosis and treatment are usually quite challenging. The standard techniques of diagnosis, like MRI and CT scans, often lack the ability to detect the disease in its early stages, while invasive ones like biopsy may include certain discomfort and risks. Nanotechnology, a type of technology that operates at the molecular level, offers solutions to these challenges. It talks about the application of nanotechnology in the detection and treatment of early-stage breast cancer, focusing on nano-enabled biosensors and nanoparticles. Nano-enabled biosensors can detect cancer biomarkers in body liquids, providing a non-invasive alternative to the conventional techniques of imaging. At the same time, nanoparticles enhance treatment efficacy owing to their potential for precise targeting of cancer cells, which reduces the side effects compared to conventional chemotherapy. This review also explores recent preclinical and clinical studies discussing the latest advances, such as bifunctional nanoprobes, fluorescent nano sensors, and ultra-pH-sensitive nanoparticles. Despite these advances, certain challenges remain regarding both biocompatibility and long-term safety. Continued research and exploration will be necessary fully to utilize the potential of nanotechnology in improving the detection and treatment of breast cancer. Basically, nanotechnology represents a huge step in the development of early detection and effective treatments, which can ensure happier and healthier patients.
Downloads
References or Bibliography
National Cancer Institute. (2017, August 8). Current Nanotechnology Treatments. National Cancer Institute; Cancer.gov. https://www.cancer.gov/nano/cancer-nanotechnology/current-treatments
Breast Cancer Early Detection and Diagnosis | How To Detect Breast Cancer. (n.d.). Www.cancer.org. https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection.html
Preliminary Cancer Incidence Rates and Trends. (n.d.). SEER. https://seer.cancer.gov/statistics/preliminary-estimates/
dos Santos Jesus, V. P., Vieira, P. F. A., Cintra, R. C., Sant’Anna, L. B., Zezell, D. M., Castilho, M. L., & Raniero, L. (2022). Triple-negative breast cancer treatment in xenograft models by bifunctional nanoprobes combined to photodynamic therapy. Photodiagnosis and Photodynamic Therapy, 38, 102796. https://doi.org/10.1016/j.pdpdt.2022.102796
Gaikwad, P. V., Rahman, N., Ghosh, P., Ng, D., & Williams, R. M. (2024). Rapid differentiation of estrogen receptor status in patient biopsy breast cancer aspirates with an optical nanosensor. BioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2024.03.29.587397
Orrantia-Borunda, E., Anchondo-Nuñez, P., Acuña-Aguilar, L. E., Gómez-Valles, F. O., & Ramírez-Valdespino, C. A. (2022). Subtypes of Breast Cancer(H. N. Mayrovitz, Ed.). PubMed; Exon Publications. https://www.ncbi.nlm.nih.gov/books/NBK583808/#:~:text=Accordingly%2C%20the%20following%20four%20subtypes
Haldavnekar, R., Venkatakrishnan, K., & Tan, B. (2022). Cancer Stem Cell Derived Extracellular Vesicles with Self-Functionalized 3D Nanosensor for Real-Time Cancer Diagnosis: Eliminating the Roadblocks in Liquid Biopsy. ACS Nano, 16(8), 12226–12243. https://doi.org/10.1021/acsnano.2c02971
Feng, Q., Wilhelm, J., & Gao, J. (2019). Transistor-like Ultra-pH-Sensitive Polymeric Nanoparticles. Accounts of Chemical Research, 52(6), 1485–1495. https://doi.org/10.1021/acs.accounts.9b00080
Breast cancer: Different types, different treatments. (n.d.). Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/breast-cancer/in-depth/breast-cancer/art-20045654#:~:text=Breast%20cancer%20groups%20include%3A
National Cancer Institute. (2017, August 8). Benefits of Nanotechnology for Cancer. National Cancer Institute; Cancer.gov. https://www.cancer.gov/nano/cancer-nanotechnology/benefits
(2024). Clinicaltrials.gov. https://clinicaltrials.gov/study/NCT00639171?cond=breast%20cancer&term=Detection&rank=3
Kemp, J. A., & Kwon, Y. J. (2021). Cancer nanotechnology: current status and perspectives. Nano Convergence, 8(1). https://doi.org/10.1186/s40580-021-00282-7
Cheng, Z., Li, M., Dey, R., & Chen, Y. (2021). Nanomaterials for cancer therapy: current progress and perspectives. Journal of Hematology & Oncology, 14(1). https://doi.org/10.1186/s13045-021-01096-0
Chehelgerdi, M., Matin Chehelgerdi, Omer Qutaiba Al-lela, Cosme, D., Narayanan Jayasankar, Devendra Pratap Rao, Tamilanban Thamaraikani, Manimaran Vasanthan, Patrik Viktor, Natrayan Lakshmaiya, Saadh, M. J., Amajd, A., Abo‐Zaid, M. A., Roxana Yolanda Castillo-Acobo, Ismail, A. H., Amin, A. H., & Reza Akhavan‐Sigari. (2023). Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Molecular Cancer, 22(1). https://doi.org/10.1186/s12943-023-01865-0
IHC Test for HER-2 Positive Breast Cancer: Uses, Procedure, Accuracy. (2022, April 28). Healthline. https://www.healthline.com/health/breast-cancer/ihc-test
Yu, X., & Zhu, L. (2024). Nanoparticles for the Treatment of Bone Metastasis in Breast Cancer: Recent Advances and Challenges. International Journal of Nanomedicine, 19, 1867–1886. https://doi.org/10.2147/IJN.S442768
Chen, Y., Wu, X., Li, J., Jiang, Y., Xu, K., & Su, J. (2022). Bone-Targeted Nanoparticle Drug Delivery System: An Emerging Strategy for Bone-Related Disease. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.909408
Ramesh, M., Janani, R., Deepa, C., & Rajeshkumar, L. (2022). Nanotechnology-Enabled Biosensors: A Review of Fundamentals, Design Principles, Materials, and Applications. Biosensors, 13(1), 40. https://doi.org/10.3390/bios13010040
Published
How to Cite
Issue
Section
Copyright (c) 2024 Lakshmi Trivedi; Dr. Prahlad Parajuli, Professor Virgel Torremocha, Jothsna Kethar
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
